Payment overview · 2025
General Payments
$130,037.65
204 reported records · 14 companies
Healthcare provider profile · identity verified
Robert Daniel Davis, D.P.M.
Podiatric Medicine & Surgery Service Providers|Podiatrist · BRIDGEPORT, CT · NPI 1801975537
Verified facts
What the public records show
CMS Open Payments records show Robert Daniel Davis, D.P.M. received $130,037.65 in general payments during 2025 across 204 reported records.
Smith+Nephew, Inc. accounted for 53.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jublia.
Ortho Dermatologics, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JUBLIA as an associated drug or biological on 5397 records involving 2963 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jublia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $69,723.02 | 53.6% | 68 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $59,438.75 | 45.7% | 106 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $325.09 | 0.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $115.36 | 0.1% | 5 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $110.25 | 0.1% | 7 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $109.52 | 0.1% | 5 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $69.49 | 0.1% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $28.18 | 0.0% | 1 | 2025 |
| Hydrofera LLC | Unresolved — no canonical attribution shown | $22.84 | 0.0% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $20.98 | 0.0% | 1 | 2025 |
| Sanara MedTech Inc. | Unresolved — no canonical attribution shown | $19.80 | 0.0% | 1 | 2025 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.71 | 0.0% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $17.68 | 0.0% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $16.98 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $70,167.50 | 17 |
| Consulting Fee | $36,210.00 | 7 |
| Travel and Lodging | $19,985.64 | 104 |
| Food and Beverage | $3,674.51 | 76 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GRAFIX Normalized: grafix |
Biological | Smith+Nephew, Inc. | $64,622.72 | 39 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $49,606.50 | 36 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $48,772.57 | 72 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $40,220.60 | 28 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $37,493.57 | 45 | 2025 |
Source payment records
|
|||||
| NOVACHOR Normalized: novachor |
Medical Supply | Organogenesis Inc. | $37,318.97 | 43 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $27,206.27 | 17 | 2025 |
Source payment records
|
|||||
| NUSHIELD Normalized: nushield |
Medical Supply | Organogenesis Inc. | $27,016.83 | 14 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $10,763.61 | 9 | 2025 |
Source payment records
|
|||||
| GRAFIX XC Normalized: grafix xc |
Biological | Smith+Nephew, Inc. | $10,175.00 | 2 | 2025 |
Source payment records
|
|||||
| NA Normalized: na |
Device | Smith+Nephew, Inc. | $10,175.00 | 2 | 2025 |
Source payment records
|
|||||
| STRAVIX MESH Normalized: stravix mesh |
Biological | Smith+Nephew, Inc. | $6,056.87 | 3 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $2,838.68 | 7 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $297.70 | 5 | 2025 |
Source payment records
|
|||||
| ACTISHIELD Normalized: actishield |
Device | Stryker Corporation | $160.44 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $115.36 | 5 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $110.25 | 7 | 2025 |
Source payment records
|
|||||
| PROMOGRAN PRISMA Normalized: promogran prisma |
Device | Solventum Corporation | $80.56 | 3 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO Normalized: v a c veraflo |
Device | Solventum Corporation | $80.56 | 3 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $80.24 | 4 | 2025 |
Source payment records
|
|||||
| DART-FIRE Normalized: dart fire |
Device | Stryker Corporation | $58.40 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $52.06 | 2 | 2025 |
Source payment records
|
|||||
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $47.97 | 1 | 2025 |
Source payment records
|
|||||
| VARIAX Normalized: variax |
Device | Stryker Corporation | $34.85 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.ULTA Normalized: v a c ulta |
Device | Solventum Corporation | $28.96 | 2 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. iOn PROGRESS Normalized: activ a c ion progress |
Device | Solventum Corporation | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| ALLOWRAP Normalized: allowrap |
Device | Stryker Corporation | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| HYDROFERA BLUE READY - BORDER Normalized: hydrofera blue ready border |
Device | Hydrofera LLC | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| Iodosorb Ointment 40g USA Normalized: iodosorb ointment 40g usa |
Device | Smith+Nephew, Inc. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| REGRANEX Normalized: regranex |
Drug | Smith+Nephew, Inc. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| FILSUVEZ Normalized: filsuvez |
Drug | Chiesi USA, Inc. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| CellerateRX Normalized: celleraterx |
Device | Sanara MedTech Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| JUBLIA Normalized: jublia |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ Normalized: aquacel ag |
Device | ConvaTec Inc. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JUBLIA jublia |
2025 | Jublia | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Ortho Dermatologics, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | JUBLIA open payments reported associated product |
CMS Open Payments — General Payments 5397 supporting records · 2963 recipient NPIs · example record 1220077864 |
Jublia · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Meloxicam | Meloxicam | 141 | 59 |
| Jublia | Efinaconazole | 36 | 12 |
| Cephalexin | Cephalexin | 35 | 28 |
| Celecoxib | Celecoxib | 31 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Ciclopirox | Ciclopirox Olamine | 12 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130,037.65 · 204 records | Smith+Nephew, Inc. | ACTISHIELD, ACTIV.A.C., ACTIV.A.C. iOn PROGRESS, AFFINITY, ALLOWRAP, APLIGRAF, AQUACEL AG+, AUGMENT INJECTABLE, COLLAGENASE SANTYL, CellerateRX, DART-FIRE, EXOGEN ULTRASOUND BONE HEALING SYSTEM, FILSUVEZ, GRAFIX, GRAFIX PL, GRAFIX XC, HYDROFERA BLUE READY - BORDER, Iodosorb Ointment 40g USA, JUBLIA, KRYSTEXXA, Miro3D, NA, NOVACHOR, NUSHIELD, NUZYRA, OASIS, PREVENA, PROMOGRAN PRISMA, PURAPLY WOUND MATRIX, REGRANEX, RENASYS TOUCH, STRAVIX, STRAVIX MESH, STRAVIX PL, V.A.C. VERAFLO, V.A.C.ULTA, VARIAX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jublia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Ortho Dermatologics, a division of Bausch Health US, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error